Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease (Q47271726)

13 January 2018

title

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease (English)

1 reference

13 January 2018

1 reference

1 reference

9

Paul Rutgeerts

1 reference

13 January 2018

1

Stephen B Hanauer

1 reference

13 January 2018

author name string

Carrie L Wagner

2

1 reference

13 January 2018

Mohan Bala

3

1 reference

13 January 2018

Lloyd Mayer

4

1 reference

13 January 2018

Suzanne Travers

5

1 reference

13 January 2018

Robert H Diamond

6

1 reference

13 January 2018

Allan Olson

7

1 reference

13 January 2018

Warren Bao

8

1 reference

13 January 2018

language of work or name

English

0 references

publication date

1 July 2004

1 reference

13 January 2018

Clinical Gastroenterology and Hepatology

published in

1 reference

13 January 2018

volume

2

1 reference

13 January 2018

page(s)

542-553

1 reference

13 January 2018

issue

7

1 reference

13 January 2018

Therapeutic antibodies: magic bullets hit the target.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Immunogenicity of recombinant DNA human insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Tumour necrosis factor alpha in stool as a marker of intestinal inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Role of cytokines in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900238-1

7 January 2021

10.1016/S1542-3565(04)00238-1

Identifiers

DOI

1 reference

13 January 2018

PubMed ID

15224278

1 reference

13 January 2018